Atlas Trials

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Clinical trial NCT04684108 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04684108
Sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple MyelomaHematological Malignancy
Start date
2021-11-04
Primary completion
2024-06-30
Enrollment
61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.